Skip to main content

peginterferon beta-1a

Generic: peginterferon beta-1a·Brand: Plegridy

peginterferon beta-1a: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

peginterferon beta-1a evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect peginterferon beta-1a to BIIB; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could peginterferon beta-1a → BIIB affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Multiple Sclerosis

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
BIOGEN INC. (BIIB)
Multiple Sclerosis
—
BIOGEN INC. (BIIB)Approved
Clinical Trials (1)

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

NCT05688436·BIIB
Active, not recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational1,178 targetStarted 2021-09Completion 2031-011 site · United StatesBiogen
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )(BIIB)FDA ↗
BLA125499Type 1 - New Molecular EntityStandardOtherInjectable

Frequently asked questions

Who is developing peginterferon beta-1a?

peginterferon beta-1a is being developed by BIOGEN INC..

How many clinical trials involve peginterferon beta-1a?

BioSniper tracks 1 clinical trial involving peginterferon beta-1a.

What is peginterferon beta-1a's latest FDA decision?

The most recent tracked FDA decision for peginterferon beta-1a is Approval for 1 INDICATIONS AND USAGE PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ), dated August 15, 2014.